Actionable news
0
All posts from Actionable news
Actionable news in ALNY: Alnylam Pharmaceuticals, Inc.,

12 Upcoming Phase 3 data readouts for 3Q 2017; Biotech Week in Review ~ August 11, 2017

Weekly watchlist

The mid-point of 3Q 2017 swiftly is approaching while the finish line for the current earnings season is thankfully just around the corner with most companies expected to have reported by early next week. Each earnings season provides a valuable opportunity to update key biotech catalysts featured on BioPharmCatalyst to ensure accuracy is maintained to the highest level. Remaining 2H 2017 catalysts will be double checked at the end of next week to ensure latest timelines provided in earnings reports match the calendar entries.

This week’s BioPharmCatalyst Weekly Biotech Watch List focuses on key Phase 3 data readouts due this current quarter. Firstly though, let’s review five key events from the week that was.

Kite Pharma Inc (NASDAQ:KITE) announced that the FDA has advised an Advisory Committee Meeting will not be required for its regulatory filing for its CAR-T candidate, Axi-cel, for the treatment of Non-Hodgkin's Lymphoma (NHL). The PDUFA date under priority review is set for November 29, 2017.

FibroGen, Inc. (NASDAQ:FGEN) shares closed the week up 19% to $41.65. The company announced that top-line data from its Phase 2 trial of pamrevlumab in...


More